101 related articles for article (PubMed ID: 26760246)
1. Simple alternative to sialic acid determination in meningococcal polysaccharides W or Y.
Morduš M; Štimac A; Brgles M; Kurtović T; Halassy B
J Pharm Biomed Anal; 2016 Feb; 120():283-9. PubMed ID: 26760246
[TBL] [Abstract][Full Text] [Related]
2. Quantification of each serogroup polysaccharide of Neisseria meningitidis in A/C/Y/W-135-DT conjugate vaccine by high-performance anion-exchange chromatography-pulsed amperometric detection analysis.
Gudlavalleti SK; Crawford EN; Harder JD; Reddy JR
Anal Chem; 2014 Jun; 86(11):5383-90. PubMed ID: 24810004
[TBL] [Abstract][Full Text] [Related]
3. Four monoclonal antibodies against capsular polysaccharides of Neisseria meningitidis serogroups A, C, Y and W135: its application in identity tests.
Reyes F; Amin N; Otero O; Aguilar A; Cuello M; Valdés Y; García LG; Cardoso D; Camacho F
Biologicals; 2013 Jul; 41(4):275-8. PubMed ID: 23791517
[TBL] [Abstract][Full Text] [Related]
4. Determination of meningococcal serogroups in formulated monovalent and multivalent polysaccharide and polysaccharide-conjugate vaccines.
Cook MC; Kunkel JP
Anal Chem; 2015 May; 87(9):5009-11. PubMed ID: 25837841
[No Abstract] [Full Text] [Related]
5. Quantitation of serogroups in multivalent polysaccharide-based meningococcal vaccines: optimisation of hydrolysis conditions and chromatographic methods.
Cook MC; Bliu A; Kunkel JP
Vaccine; 2013 Aug; 31(36):3702-11. PubMed ID: 23764533
[TBL] [Abstract][Full Text] [Related]
6. Clinical manifestations of invasive meningococcal disease in Victoria with the emergence of serogroup W and serogroup Y Neisseria meningitidis.
Birrell MT; Strachan J; Holmes NE; Stevens K; Howden BP; Franklin LJ; Ivan M; Kwong JC
Intern Med J; 2021 Mar; 51(3):390-397. PubMed ID: 32043702
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
8. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
9. A novel monoclonal antibody to Neisseria meningitidis serogroup X capsular polysaccharide and its potential use in quantitation of meningococcal vaccines.
Reyes F; Otero O; Camacho F; Amin N; Ramírez F; Valdés Y; Acevedo R; García L; Cardoso D; Cuello M
Biologicals; 2014 Nov; 42(6):312-5. PubMed ID: 25218518
[TBL] [Abstract][Full Text] [Related]
10. Relative stability of meningococcal serogroup A and X polysaccharides.
Berti F; Romano MR; Micoli F; Pinto V; Cappelletti E; Gavini M; Proietti D; Pluschke G; MacLennan CA; Costantino P
Vaccine; 2012 Oct; 30(45):6409-15. PubMed ID: 22921741
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of candidate international standards for meningococcal serogroups A and X polysaccharide.
Vipond C; Swann CJ; Dougall TW; Rigsby P; Gao F; Beresford NJ; Bolgiano B;
Biologicals; 2017 May; 47():33-45. PubMed ID: 28389172
[TBL] [Abstract][Full Text] [Related]
12. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
Cohen R; Levy C
Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
[TBL] [Abstract][Full Text] [Related]
13. Serogroup quantitation of multivalent polysaccharide and polysaccharide-conjugate meningococcal vaccines from China.
Cook MC; Gibeault S; Filippenko V; Ye Q; Wang J; Kunkel JP
Biologicals; 2013 Jul; 41(4):261-8. PubMed ID: 23665303
[TBL] [Abstract][Full Text] [Related]
14. Expanding prevention of invasive meningococcal disease.
Pelton SI; Gilmet GP
Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.
Gudlavalleti SK; Lee CH; Norris SE; Paul-Satyaseela M; Vann WF; Frasch CE
Vaccine; 2007 Nov; 25(46):7972-80. PubMed ID: 17936445
[TBL] [Abstract][Full Text] [Related]
16. Amino acid 310 determines the donor substrate specificity of serogroup W-135 and Y capsule polymerases of Neisseria meningitidis.
Claus H; Stummeyer K; Batzilla J; Mühlenhoff M; Vogel U
Mol Microbiol; 2009 Feb; 71(4):960-71. PubMed ID: 19170877
[TBL] [Abstract][Full Text] [Related]
17. [Neisseria meningitidis: characterisation and epidemiology].
Raymond J
Arch Pediatr; 2012 Sep; 19 Suppl 2():S55-60. PubMed ID: 22883367
[TBL] [Abstract][Full Text] [Related]
18. Annual report of the Australian Meningococcal Surveillance Programme, 2007.
Tapsall J;
Commun Dis Intell Q Rep; 2008 Sep; 32(3):299-307. PubMed ID: 19062765
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Escherichia coli K1 colominic acid-specific murine antibodies that are cross-protective against Neisseria meningitidis groups B, C, and Y.
Park IH; Lin J; Choi JE; Shin JS
Mol Immunol; 2014 Jun; 59(2):142-53. PubMed ID: 24603121
[TBL] [Abstract][Full Text] [Related]
20. Immunochemical studies and genetic background of two Neisseria meningitidis isolates expressing unusual capsule polysaccharide antigens with specificities of both serogroup Y and W135.
Tsang RS; Tsai CM; Henderson AM; Tyler S; Law DK; Zollinger W; Jamieson F
Can J Microbiol; 2008 Mar; 54(3):229-34. PubMed ID: 18388994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
